Epizyme, Inc. to Present at Upcoming Conferences in February

CAMBRIDGE, Mass., Feb. 7, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced it will present a company overview at the following conferences in February:

• 16th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on Tuesday, February 11 at 3:30 p.m. ET. A live webcast will be available at this link or by visiting the Investor Center of the Epizyme website at www.epizyme.com. An archived replay of the webcast will be available on the Company's website for 30 days after the conference.
• 2014 Leerink Global Healthcare Conference at the Waldorf Astoria Hotel in New York on Wednesday, February 12 at 2:15 p.m. ET. A live webcast will be available at this link or by visiting the Investor Center of the Epizyme website at www.epizyme.com. An archived replay of the webcast will be available on the Company's website for 30 days after the conference.
• Citi 2014 Global Healthcare Conference at the Hilton New York Hotel in New York on Wednesday, February 26 at 10:30 a.m. ET.

About Epizyme, Inc.
Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.

For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.

SOURCE Epizyme, Inc.